[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.157.19.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
March 23/30, 2005

Inhibitors of Ocular NeovascularizationPromises and Potential Problems

Author Affiliations
 

Author Affiliations: Department of Ophthalmology, Flinders University of South Australia, Adelaide, Australia.

JAMA. 2005;293(12):1509-1513. doi:10.1001/jama.293.12.1509

Molecular medicine offers promise for the prevention of vision loss caused by ocular neovascularization in diabetic retinopathy and exudative age-related macular degeneration (ARMD). During the past decade, significant advances have been made in angiogenesis research, such that the understanding about new vessel formation in disease has increased considerably. This knowledge has led to the development of numerous inhibitors of angiogenesis. Among a host of novel therapeutics for ocular neovascularization, 2 inhibitors of the angiogenic agent vascular endothelial growth factor (VEGF)—pegaptanib sodium and ranibizumab—are poised for imminent clinical application. However, the need for repeated intraocular injection of these agents and the potential for local and systemic adverse effects may pose hurdles for these emerging therapies.

First Page Preview View Large
First page PDF preview
First page PDF preview
×